When Will Semaglutide Go Generic? The Real Timeline
Canada already has generic semaglutide. The US will not, for years. The difference comes down to patent geography - and one missed maintenance fee. Here is the country-by-country timeline, and an honest assessment of how much cheaper generics will actually make it.
Last updated: August 3, 2026
Quick Answer
It depends entirely on where you live, and the spread is enormous. Canada's semaglutide compound patent expired in early 2026, and Health Canada has approved a generic semaglutide from Dr. Reddy's - a first among G7 countries. China's patent is also set to expire in 2026. In the United States, semaglutide remains under patent, with exclusivity expected to run into the early 2030s in many markets.
Canada's early opening was partly an accident of administration. The compound patent (CA2601784) was scheduled to expire in March 2026, but Novo Nordisk failed to pay a maintenance fee, and a separate regulation expired on January 5, 2026 - which cleared the path sooner than the drug maker intended.
Temper your expectations on price. Liraglutide - the first GLP-1 to go generic in the US - dropped only about 30% below brand, not the 80-90% typical of ordinary generics. Peptide manufacturing is complex, and few competitors enter. Expect a similar pattern for semaglutide.
Country-by-Country Timeline
Semaglutide patents were filed and granted separately in each jurisdiction, so expiry dates vary widely. This is the single most misunderstood point in the whole discussion - "semaglutide goes generic in 2026" is true and false at the same time, depending on your address.
| Market | Patent Status | Generic Availability |
|---|---|---|
| Canada | Compound patent CA2601784 expiry March 20, 2026; lapsed earlier after unpaid maintenance fee | Generic approved - Dr. Reddy's, a G7 first |
| China | Patent set to expire in 2026 | Expected - potentially the largest generic market |
| United States | Still under patent | Not expected until the early 2030s |
| Most other markets | Protected into the early 2030s | Staggered, market by market |
Industry analysis has framed off-patent semaglutide as the next major shift in anti-obesity treatment - but with the important caveat that it arrives in different countries years apart. Semaglutide will remain under patent in many countries until the early 2030s even as generics circulate elsewhere.
Why patents expire at different times. A pharmaceutical company files patents jurisdiction by jurisdiction, and each national patent office grants its own term. Filing dates, term extensions, supplementary protection certificates, and pediatric exclusivity all differ. On top of that, patents must be actively maintained - which is exactly where Canada's timeline diverged.
What Happened in Canada
Canada's situation is genuinely unusual and worth understanding, because it is being widely misreported as a normal patent expiry.
The compound patent for semaglutide in Canada, CA2601784, was scheduled to expire on March 20, 2026. Canada's certificate of supplementary protection register lists semaglutide against that patent. But reporting indicates Novo Nordisk failed to pay a required maintenance fee, causing the patent to lapse ahead of its scheduled term. A separate regulation expired on January 5, 2026.
The result: Canada became the first G7 country to approve a generic semaglutide, from Dr. Reddy's Laboratories. For a drug generating this much revenue, an unpaid maintenance fee is a remarkable administrative outcome.
Approval is not the same as availability. Regulatory approval, manufacturing scale-up, distribution agreements, and provincial formulary listings are separate steps. Reporting at the time of the patent lapse noted that generics were not immediately imminent despite the legal path opening. Expect a lag between "approved" and "on the shelf at a normal price."
The US Outlook
For American readers, this is the section that matters, and the answer is not encouraging in the short term.
Semaglutide remains under patent in the United States, with exclusivity expected to extend into the early 2030s. Nothing about Canada's lapsed patent affects US protection - patents are national rights, and a lapse in one country has no bearing on another.
Several factors could shift the US timeline in either direction:
- Patent challenges. Generic manufacturers routinely challenge patents before expiry. Success can accelerate entry; failure extends exclusivity.
- Settlement agreements. Brand and generic makers sometimes settle litigation with an agreed entry date earlier than full patent term.
- Additional patents. Beyond the compound patent, formulation, device, and manufacturing patents can extend effective exclusivity past the primary date.
- Policy intervention. Federal pricing action has already reshaped GLP-1 costs in the US through manufacturer self-pay programs and the Medicare GLP-1 Bridge, without waiting for generics.
The practical point: do not plan your health around waiting for generic semaglutide in the US. A timeline measured in years, with real uncertainty attached, is not a treatment plan. Meanwhile, manufacturer self-pay pricing has already brought brand-name GLP-1s into the $149-$449 range - which is likely close to where early generics would land anyway.
How Cheap Will Generic Semaglutide Actually Be?
The common assumption is that generics mean a 90% price drop. For peptide drugs like semaglutide, that assumption is wrong.
| Drug Type | Typical Generic Discount | Why |
|---|---|---|
| Small molecule (e.g. statins) | 80-90% below brand | Cheap to synthesize; dozens of manufacturers compete |
| Peptide (e.g. liraglutide) | ~30% below brand | Complex manufacturing; high barriers; few entrants |
Semaglutide is a peptide. Manufacturing it requires specialized capability, substantial capital investment, and regulatory demonstration of bioequivalence for an injectable product. That keeps the number of competitors low, and price competition requires many competitors, not two or three.
There is also a device dimension. Semaglutide is delivered by injection pen, and pen technology carries its own patents. A generic manufacturer may need to design around those, which adds cost and complexity beyond the molecule itself.
A realistic expectation for early US generic semaglutide, whenever it arrives, is a meaningful discount to brand list price - but not necessarily below what manufacturer self-pay programs already offer today. Wegovy already starts at $149/month at lower doses through NovoCare.
The Liraglutide Lesson
We do not have to speculate about how GLP-1 generics behave. Liraglutide already went generic in the US, and the results are instructive.
- Generic entry was fast once exclusivity lapsed. Hikma received FDA approval for the first generic liraglutide injection in December 2024, and Teva launched a generic Saxenda in 2025.
- The discount was about 30%, not 90%. Teva set a wholesale acquisition cost around $1,165 against roughly $1,350 for branded Saxenda.
- The generic still cost more than newer brand-name drugs on self-pay. Generic Saxenda at ~$1,165 wholesale exceeds Zepbound at $299-$449 through LillyDirect - while delivering far less weight loss.
- Discount cards mattered more than the generic itself. Some of the lowest real-world liraglutide prices came through coupon programs, not from generic competition.
The full story is in our generic liraglutide guide. The short version: generic status is not the same as cheap.
Can You Import It From Canada?
This question follows immediately from the Canadian news, and the honest answer is that personal importation of prescription medication into the US is generally not permitted under federal law, with narrow exceptions that are applied case by case rather than as a general right.
We are not going to walk you through workarounds. Beyond the legal issue, cross-border purchasing of injectable medication introduces real practical risks: no guarantee of cold-chain integrity in transit, no US prescriber managing your titration or monitoring for pancreatitis and gallbladder complications, and no recourse if the product is not what it claims to be. Websites offering to ship prescription GLP-1s internationally are frequently not operating within any regulatory framework at all.
If cost is the driver - which it almost always is - there are legitimate US routes that have become dramatically cheaper in the past year. Those are covered below.
What to Do While You Wait
The strongest argument against waiting for generics is that the affordable options already arrived - just through a different mechanism than patent expiry.
| Option | Monthly Cost | Available Now? |
|---|---|---|
| Medicare GLP-1 Bridge | $50 copay | Yes, for eligible Part D beneficiaries |
| Wegovy self-pay (NovoCare) | $149-$399 by dose | Yes |
| Zepbound self-pay vials | $299-$449 by dose | Yes |
| Foundayo (LillyDirect) | $149-$349 | Yes |
| Compounded semaglutide | $249-$399 all-in | Yes, via licensed programs |
Every row on that table is available today, and several are at or below what early generic pricing would realistically deliver. Meanwhile, the health costs of untreated obesity - on your cardiovascular system, joints, glucose metabolism, and sleep - accumulate the entire time you wait.
For the full comparison, see our guides to the cheapest semaglutide and cheapest GLP-1 options.
Affordable Semaglutide Available Today
You do not need to wait for a patent to expire. Coreage Rx offers physician-supervised compounded semaglutide from $249/month, with the medical consultation, medication, shipping, and ongoing dose management included in one flat price - no insurance required.
Frequently Asked Questions
Is there a generic for semaglutide in Canada?
Yes. Health Canada approved a generic semaglutide from Dr. Reddy's - the first among G7 countries - after Novo Nordisk's Canadian compound patent (CA2601784) lapsed. The patent was scheduled to expire March 20, 2026, but reportedly lapsed earlier following an unpaid maintenance fee, with a separate regulation expiring January 5, 2026. Approval and wide availability at low prices are separate things, so expect a lag.
When will semaglutide be generic in the United States?
Not soon. Semaglutide remains under patent in the US, with exclusivity expected to run into the early 2030s. Canada's lapsed patent has no effect on US protection - patents are national rights. Patent challenges, litigation settlements, and secondary formulation or device patents could shift the date in either direction, so treat any specific year you see quoted with caution.
How much cheaper will generic semaglutide be?
Probably less than you expect. Liraglutide, the first GLP-1 to go generic in the US, launched around 30% below brand - not the 80-90% typical of small-molecule generics. Peptides are complex and expensive to manufacture, so few competitors enter, and real price competition requires many. Injection pen patents add further complexity. Early generic semaglutide may not undercut what manufacturer self-pay programs already offer.
Which countries lose semaglutide patent protection in 2026?
Canada and China are the notable ones. Canada's compound patent was scheduled for March 2026 expiry and lapsed earlier, and China's patent is set to expire in 2026 - potentially creating the largest generic semaglutide market by volume. Most other markets, including the US, remain protected into the early 2030s.
Can I buy generic semaglutide from Canada?
Personal importation of prescription medication into the US is generally not permitted under federal law. Beyond the legal issue, importing injectable medication carries real practical risks: no guarantee of cold-chain integrity in transit, no US prescriber monitoring your titration or watching for complications like pancreatitis and gallbladder disease, and no recourse if the product is not what it claims. Legitimate US routes have become substantially cheaper - compare those first.
Is compounded semaglutide the same as generic semaglutide?
No, and this is an important distinction. A generic is an FDA-approved finished product that must demonstrate bioequivalence to the brand and is made under full pharmaceutical manufacturing standards. Compounded semaglutide is prepared by a licensed pharmacy for individual patients - a legitimate regulated pathway, but not an FDA-approved product and not subject to bioequivalence testing. Note also that per the FDA's April 2026 clarification, compounded semaglutide can currently only legally come from 503A pharmacies.
Should I wait for generics before starting treatment?
Generally no. A US timeline measured in years with genuine uncertainty attached is not a treatment plan, and the health costs of untreated obesity accumulate the entire time. Affordable options already exist: Wegovy self-pay from $149/month at lower doses, Zepbound vials at $299-$449, Foundayo from $149, compounded programs from $249, and a $50 copay through the Medicare GLP-1 Bridge for eligible beneficiaries.
Why did Novo Nordisk let the Canadian patent lapse?
Reporting indicates the compound patent lapsed following a failure to pay a required maintenance fee, rather than as a deliberate strategy. Patents must be actively maintained through periodic fees; missing one can cause a lapse regardless of the scheduled expiry date. For a product generating this level of revenue, it is a notable administrative outcome, and it is why Canada opened before its scheduled March 2026 date.
Disclaimer
This article is for informational purposes only and does not constitute medical or legal advice. Patent status, expiry dates, and regulatory approvals reflect publicly available reporting at the time of writing and are subject to litigation, settlement, and administrative change - nothing here should be relied on as a legal determination of patent status in any jurisdiction. Nothing in this article should be interpreted as encouragement to import prescription medication. Semaglutide is a prescription medication that should only be used under the supervision of a qualified healthcare provider. HealthyPound may receive compensation from affiliate partners mentioned in this article. See our affiliate disclosure and full medical disclaimer for more information.